Comparison of DAAs(Direct Acting Antivirals) and interferon-based triple therapy for hepatitis C after treatment of hepatocelluler carcinoma.

Comparison of DAAs(Direct Acting Antivirals) and interferon-based triple therapy for hepatitis C after treatment of hepatocelluler carcinoma. - Antiviral therapy for HCV after treatment of hepatocelluler carcinoma.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014971

Enrollment

100

Registered

2014-09-01

Start date

2014-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C after treatment for hepatocelluler carcinoma.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) HCV genotype 1b 2) Neutrophil >=1,500 /mm3 PLT >= 75,000 /mm3 3) >=3 months post HCC treatment 4) CH or LC(Child-Pugh A) 5) within HCC stage 3 6) including post PSE/splenectomy cases

Exclusion criteria

Exclusion criteria: Patients judged by doctor that participation in the study is improper

Design outcomes

Primary

Measure	Time frame
incidence of recurrence survival rate	—

Countries

Japan

Contacts

Public ContactToshie Mashiba

Matsuyama Red Cross Hospital Center for liver-Biliary-Pancreatic Diseases

matoshi@matsuyama.jrc.or.jp089-924-1111

Outcome results